ClinVar Miner

Submissions for variant NM_001166108.2(PALLD):c.1975A>G (p.Lys659Glu)

gnomAD frequency: 0.00007  dbSNP: rs370768506
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001887591 SCV002162319 uncertain significance Pancreatic adenocarcinoma 2020-12-10 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C55"). This variant has not been reported in the literature in individuals with PALLD-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces lysine with glutamic acid at codon 172 of the PALLD protein (p.Lys172Glu). The lysine residue is highly conserved and there is a small physicochemical difference between lysine and glutamic acid.
Ambry Genetics RCV004041624 SCV003573297 uncertain significance not specified 2024-11-26 criteria provided, single submitter clinical testing The p.K172E variant (also known as c.514A>G), located in coding exon 2 of the PALLD gene, results from an A to G substitution at nucleotide position 514. The lysine at codon 172 is replaced by glutamic acid, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear.
PreventionGenetics, part of Exact Sciences RCV004752095 SCV005342028 uncertain significance PALLD-related disorder 2024-06-21 no assertion criteria provided clinical testing The PALLD c.1975A>G variant is predicted to result in the amino acid substitution p.Lys659Glu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0080% of alleles in individuals of African descent in gnomAD and is interpreted as uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/1397216/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.